Internal medicine

Pharmacogenomics

SLCO1B1

Dabigatran

Atrial fibrillation

Bioinformatics

Biology

Gene

Genotype

CYP2C19

Single-nucleotide polymorphism

Warfarin

Rivaroxaban

Edoxaban

Apixaban

Cytochrome P450

Metabolism

Genetics

Pharmacogenetics

Medicine

Pharmacology

Journal of Personalized Medicine

Dabigatran, rivaroxaban, apixaban, edoxaban, and betrixaban are direct oral anticoagulants (DOACs). Their inter-individual variability in pharmacodynamics and pharmacokinetics (transport and metabolism) is high, and could result from genetic polymorphisms. As recommended by the French Network of Pharmacogenetics (RNPGx), the management of some treatments in cardiovascular diseases (as antiplatelet agents, oral vitamin K antagonists, and statins) can rely on genetic testing in order to improve healthcare by reducing therapeutic resistance or toxicity. This paper is a review of association studies between single nucleotide polymorphisms (SNPs) and systemic exposure variation of DOACs. Most of the results presented here have a lot to do with some SNPs of CES1 (rs2244613, rs8192935, and rs71647871) and ABCB1 (rs1128503, rs2032582, rs1045642, and rs4148738) genes, and dabigatran, rivaroxaban, and apixaban. Regarding edoxaban and betrixaban, as well as SNPs in the CYP3A4 and CYP3A5 genes, literature is scarce, and further studies are needed.

Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review